Healthcare Industry News: GSK
News Release - April 4, 2011
Anacor Pharmaceuticals Appoints William J. Rieflin to Its Board of DirectorsPALO ALTO, Calif.--(Healthcare Sales & Marketing Network)-- Anacor Pharmaceuticals (NASDAQ:ANAC ) announced today the appointment of William J. Rieflin to its Board of Directors. Mr. Rieflin will also serve as chair of Anacor’s Audit Committee. Mr. Rieflin brings over 20 years of industry experience to Anacor. In October 2010, he was appointed Chief Executive Officer of NGM Biopharmaceuticals, a privately held biotechnology company. Previously, he was President of XenoPort, Inc. (NASDAQ:XNPT ) and currently serves on XenoPort’s Board of Directors. Prior to that, he was Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary for Tularik, Inc. (NASDAQ:TLRK ), which was acquired by Amgen, Inc. in 2004. Previously, he was Vice President, Human Resources, General Counsel and Secretary for AMSCO International, Inc. (NYSE:ASZ ). He was also an associate at Sidley & Austin in the corporate and securities department. He began his career as a sales representative for American Hospital Supply Corporation. Mr. Rieflin earned his B.S. from Cornell University, his M.B.A. from the University of Chicago Booth School of Business and his J.D. from Stanford Law School.
“We are pleased to have Bill join the Anacor Board and chair our Audit Committee,” said David Perry, Anacor’s Chief Executive Officer. “His wealth of strategic and operational experience in the biopharmaceutical industry will be a valuable addition to our Board as we continue to build the company.”
“I am truly honored and excited to join the Anacor Board of Directors,” said Bill Rieflin. “I look forward to working with my fellow board members and the Anacor management team to maximize the value of the company’s lead compounds and its boron chemistry platform.”
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered five clinical compounds that are currently in development, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK ‘052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. For more information visit http://www.anacor.com.
This press release may contain forward-looking statements that relate to future events including the goals, plans and objectives and the future of Anacor. These forward looking statements involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements, including risks related to enrollment and successful completion of our trials, risk of unforeseen side effects, risks related to our collaborations and risks related to regulatory approval of new drug candidates. These statements reflect the views of Anacor as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
Source: Anacor Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.